BCAB Insider Trading

Insider Ownership Percentage: 11.50%
Insider Buying (Last 12 Months): $0.00
Insider Selling (Last 12 Months): $0.00

BioAtla Insider Trading History Chart

This chart shows the insider buying and selling history at BioAtla by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$0bought$0soldQ1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1-$200k-$100k$0$100k$200kTotal Insider BuyingTotal Insider Selling

BioAtla Share Price & Price History

Current Price: $0.37
Price Change: Price Decrease of -0.0193 (-4.92%)
As of 03/28/2025 05:00 PM ET

This chart shows the closing price history over time for BCAB up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365
MayJunJulAugSepOctNovDecJanFebMar$0.37Closing price on 03/28/25:

SEC Filings (Institutional Ownership Changes) for BioAtla (NASDAQ:BCAB)

77.23% of BioAtla stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at BCAB by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table
2022202320242025$5.19Mbought$876ksoldQ1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1-$4M-$2M$0$2M$4MTotal InflowsTotal Outflows
BioAtla logo
BioAtla, Inc., a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. The company's lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC), which is in Phase II clinical trial for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); and ozuriftabmab vedotin (BA3021), a CAB ADC that is in Phase II clinical trial for the treatment of melanoma and squamous cell cancer of the head and neck. It is also developing Evalstotug (BA3071), a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody, which is in Phase II clinical trial for treating melanoma, carcinomas, and NSCLC; and BA3182, a bispecific candidate that is in Phase 1 study for the treatment of adenocarcinomas, as well as BA3361, which is in preclinical studies for treating multiple tumor types. The company was founded in 2007 and is headquartered in San Diego, California.
Read More on BioAtla

Today's Range

Now: $0.37
Low: $0.28
High: $0.38

50 Day Range

MA: $0.40
Low: $0.30
High: $0.51

52 Week Range

Now: $0.37
Low: $0.24
High: $4.02

Volume

1,443,415 shs

Average Volume

994,354 shs

Market Capitalization

$18.05 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.19

Who are the company insiders with the largest holdings of BioAtla?

BioAtla's top insider shareholders include:
  1. Jay M Phd Short (CEO)
  2. Lawrence Steinman (Director)
  3. Sylvia Mcbrinn (Director)
Learn More about top insider investors at BioAtla.

Who are the major institutional investors of BioAtla?

BioAtla's top institutional investors include:
  1. Anson Funds Management LP — 9.52%
  2. Acorn Capital Advisors LLC — 8.34%
  3. Highbridge Capital Management LLC — 5.19%
  4. Tang Capital Management LLC — 2.84%
  5. Millennium Management LLC — 2.27%
  6. Renaissance Technologies LLC — 1.72%
Learn More about top institutional investors of BioAtla stock.

Which major investors are selling BioAtla stock?

In the previous quarter, BCAB stock was sold by these institutional investors:
  1. Millennium Management LLC
  2. Bank of Montreal Can
  3. Dimensional Fund Advisors LP
  4. Marshall Wace LLP
  5. Massachusetts Financial Services Co. MA
  6. Two Sigma Advisers LP
  7. Bridgeway Capital Management LLC
  8. Group One Trading LLC

Which major investors are buying BioAtla stock?

During the last quarter, BCAB stock was acquired by institutional investors including:
  1. Anson Funds Management LP
  2. Acorn Capital Advisors LLC
  3. Highbridge Capital Management LLC
  4. Boxer Capital Management LLC
  5. Jacobs Levy Equity Management Inc.
  6. Tang Capital Management LLC
  7. Norges Bank
  8. Renaissance Technologies LLC
During the last year, these company insiders have bought BioAtla stock:
  1. Jay M Phd Short (CEO)
  2. Lawrence Steinman (Director)
  3. Sylvia Mcbrinn (Director)
Learn More investors buying BioAtla stock.